SCHEMBL17955432

SCHEMBL17955432

CCOc1cc(F)ccc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RBP4 P02753 2/20 0.39
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
HRH4 Q9H3N8 3/20 0.38
EGFR P00533 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28222873 0.87 L3MBTL1 (0.41) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL14927335 0.86 HTR2C (0.46) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL18758855 0.86 L3MBTL1 (0.40) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL17688869 0.85 RBP4 (0.39) L3MBTL1CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL17955454 0.85 RBP4 (0.47) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL14850369 0.84 L3MBTL1 (0.43) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL14850067 0.80 L3MBTL1 (0.42) L3MBTL1CYP1A2CYP2D6CYP2C19TDP1
SCHEMBL22140249 0.80 HTR2C (0.46) L3MBTL1CYP2D6ALDH1A1MAPTKMT2A
SCHEMBL22140251 0.80 MAOB (0.37) L3MBTL1CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL20347958 0.80 HTR2C (0.51) RBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802125-B2 Functionalized heterocyclic compounds as antiviral agents ENANTA PHARMACEUTICALS, INC. 2023-10-31 US disclosed
US-11802125-B2 Functionalized heterocyclic compounds as antiviral agents ENANTA PHARMACEUTICALS, INC. 2023-10-31 US disclosed
US-11198693-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2021-12-14 US disclosed
US-20210292320-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2021-09-23 US disclosed
US-11000038-B2 Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients MITSUI CHEMICALS AGRO, INC. (JP) 2021-05-11 US disclosed
US-20200196600-A1 PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS MITSUI CHEMICALS AGRO, INC. (JP) 2020-06-25 US disclosed
US-20200165249-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2020-05-28 US disclosed
US-20200039996-A1 LATE SV40 (LSF) INHIBITORS TRUSTEES OF BOSTON UNIVERSITY (US) 2020-02-06 US disclosed
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2019-08-27 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 L3MBTL1 1141/4885CYP1A2 3684/4885CYP2D6 3867/4885
US-20210292320-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS HAVCR2, HDGF, HCCS L3MBTL1 4632/4885CYP1A2 304/4885CYP2D6 360/4885
US-11802125-B2 Functionalized heterocyclic compounds as antiviral agents HAVCR2, HDGF, HCCS L3MBTL1 4632/4885CYP1A2 304/4885CYP2D6 360/4885
US-20200196600-A1 PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS PNPO, PDXK, PLPBP L3MBTL1 2071/4885CYP1A2 9/4885CYP2D6 62/4885
US-20200039996-A1 LATE SV40 (LSF) INHIBITORS DNMT1, ASF1A, DOT1L L3MBTL1 855/4885CYP1A2 3930/4885CYP2D6 4460/4885
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 L3MBTL1 1141/4885CYP1A2 3684/4885CYP2D6 3867/4885
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics GTF2F1, HDGF, GTF3C5 L3MBTL1 1141/4885CYP1A2 3684/4885CYP2D6 3867/4885
US-11000038-B2 Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients PNPO, PDXK, PLPBP L3MBTL1 2071/4885CYP1A2 9/4885CYP2D6 62/4885
US-11198693-B2 Functionalized heterocycles as antiviral agents HCCS, HAVCR2, HDGF L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885
US-20200165249-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS HCCS, HAVCR2, HDGF L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.